about
Gemcitabine alone or combined with cisplatin in relapsed or refractory multiple myeloma.Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.Gemcitabine, etoposide, cisplatin, and dexamethasone in patients with refractory or relapsed non-Hodgkin's lymphoma.Cancer of the esophagus and gastric cardia: recent advances.Gemcitabine-Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta-Analysis.Phase II study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer.Prevention of lung cancer recurrence using cisplatin-loaded superhydrophobic nanofiber meshes.Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer.Pharmacological factors affecting accumulation of gemcitabine's active metabolite, gemcitabine triphosphate.The importance of schedule in whole body thermochemotherapy.Phase I trial using weekly administration of gemcitabine and docetaxel in patients with advanced pancreatic carcinoma.A rash diagnosis: Gemcitabine-associated pseudocellulitis.The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers.Standardization of the infusion sequence of antineoplastic drugs used in the treatment of breast and colorectal cancers.
P2860
Q33343492-15C75BEA-96A3-426D-8AE5-051469C9AA72Q33347071-9D7B135D-1142-45F8-A1CF-86F11ACFBD20Q33383608-654F1E86-7604-4CBB-A153-818340A7DE96Q35812817-CFF20262-BD7B-4B5E-AE23-A44EF538EC28Q36452263-BAE0C9FF-2D5E-4A32-81C5-3E038B8BC8AAQ36614893-B9934F58-41F4-4FC5-803C-0FEA8232318FQ36682970-F94708F9-D7E2-4B61-B47E-B8C89F816957Q37013079-0E706ECA-3C0E-4FC9-BBE4-0B755F6B9A71Q38673319-210699E1-E298-4AA1-BF31-C02FF47E2DABQ40011633-02B1F1E2-0CC2-4AF2-9112-17CB25BF649EQ40460037-006F6191-3823-4E4E-BA9B-F6FF3E9530C3Q40766355-5B7DF1C8-D545-4AC5-BCDC-2461CF8AF582Q48301800-9D01CB0B-5033-4C5D-A2B7-936224755314Q55111817-899295F1-36E8-472F-950A-925FE980E363
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Gemcitabine-cisplatin: a schedule finding study.
@ast
Gemcitabine-cisplatin: a schedule finding study.
@en
Gemcitabine-cisplatin: a schedule finding study.
@nl
type
label
Gemcitabine-cisplatin: a schedule finding study.
@ast
Gemcitabine-cisplatin: a schedule finding study.
@en
Gemcitabine-cisplatin: a schedule finding study.
@nl
prefLabel
Gemcitabine-cisplatin: a schedule finding study.
@ast
Gemcitabine-cisplatin: a schedule finding study.
@en
Gemcitabine-cisplatin: a schedule finding study.
@nl
P2093
P356
P1433
P1476
Gemcitabine-cisplatin: a schedule finding study
@en
P2093
C J van Groeningen
C J van Moorsel
G J Peters
H M Pinedo
J B Vermorken
P304
P356
10.1023/A:1008339425708
P577
1999-12-01T00:00:00Z